Maria Efthymiou

1.9k total citations · 1 hit paper
31 papers, 833 citations indexed

About

Maria Efthymiou is a scholar working on Rheumatology, Hematology and Surgery. According to data from OpenAlex, Maria Efthymiou has authored 31 papers receiving a total of 833 indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Rheumatology, 17 papers in Hematology and 10 papers in Surgery. Recurrent topics in Maria Efthymiou's work include Systemic Lupus Erythematosus Research (23 papers), Platelet Disorders and Treatments (10 papers) and Blood Coagulation and Thrombosis Mechanisms (10 papers). Maria Efthymiou is often cited by papers focused on Systemic Lupus Erythematosus Research (23 papers), Platelet Disorders and Treatments (10 papers) and Blood Coagulation and Thrombosis Mechanisms (10 papers). Maria Efthymiou collaborates with scholars based in United Kingdom, Italy and Australia. Maria Efthymiou's co-authors include Hannah Cohen, David Isenberg, Ian Mackie, Deepa J. Arachchillage, Samuel J. Machin, Beverley J. Hunt, Andrew Lawrie, Munther A. Khamashta, María Laura Bertolaccini and Simon Clawson and has published in prestigious journals such as Blood, PLoS ONE and Clinical Chemistry.

In The Last Decade

Maria Efthymiou

31 papers receiving 815 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): a randomised, controlled, open-label, phase 2/3, non-inferiority trial

2016 278 citations Hannah Cohen, Beverley J. Hunt et al. The Lancet Haematology profile →

Peers

Countries citing papers authored by Maria Efthymiou

Since Specialization

Citations

This map shows the geographic impact of Maria Efthymiou's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Maria Efthymiou with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Maria Efthymiou more than expected).

Fields of papers citing papers by Maria Efthymiou

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Maria Efthymiou. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Maria Efthymiou. The network helps show where Maria Efthymiou may publish in the future.

Co-authorship network of co-authors of Maria Efthymiou

This figure shows the co-authorship network connecting the top 25 collaborators of Maria Efthymiou. A scholar is included among the top collaborators of Maria Efthymiou based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Maria Efthymiou. Maria Efthymiou is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Comparison of clinical and serological features in thrombotic antiphospholipid syndrome patients, with and without associated systemic lupus erythematosus, followed for up to 42 years: A single centre retrospective study 2024 ·Lupus ·(unknown), (unknown), (unknown), (unknown), (unknown), Hannah Cohen, Maria Efthymiou, David Isenberg	1
2	Can complement activation be the missing link in antiphospholipid syndrome? 2024 ·Lara D. Veeken ·(unknown), (unknown), (unknown), David Isenberg, Hannah Cohen, Maria Efthymiou	7
3	Viewpoint: Lupus anticoagulant detection and interpretation in antiphospholipid syndrome 2024 ·Lara D. Veeken ·Maria Efthymiou, María Laura Bertolaccini, Hannah Cohen	1
4	Platelets and Thrombotic Antiphospholipid Syndrome 2024 ·Journal of Clinical Medicine ·(unknown), (unknown), David Isenberg, Hannah Cohen, Maria Efthymiou	8
5	Fluctuation of Anti–Domain 1 and Anti–β₂‐Glycoprotein I Antibody Titers Over Time in Patients With Persistently Positive Antiphospholipid Antibodies 2023 ·Arthritis & Rheumatology ·Cecilia Beatrice Chighizola, Francesca Pregnolato, Danieli Andrade, Maria G. Tektonidou, Vittorio Pengo, Guillermo Ruiz‐Irastorza, H. Michael Belmont, Maria Gerosa, Paul R. Fortin, D. Ware Branch, Laura Andréoli, Michelle Petri, Ricard Cervera, Jason S. Knight, Rohan Willis, Maria Efthymiou, Hannah Cohen, Doruk Erkan, María Laura Bertolaccini	12
6	Energy-Efficient and Adaptive Gradient Sparsification for Federated Learning 2023 ·KTH Publication Database DiVA (KTH Royal Institute of Technology) ·(unknown), Maria Efthymiou, Sindri Magnússon	5
7	Coexistent antiphospholipid syndrome and myeloproliferative neoplasm 2021 ·Lupus ·(unknown), (unknown), Maria Efthymiou, Jonathan Lambert, Hannah Cohen	2
8	Anti-protein C antibodies and acquired protein C resistance in SLE: novel markers for thromboembolic events and disease activity? 2020 ·Lara D. Veeken ·Giuseppe A. Ramirez, Ian Mackie, (unknown), (unknown), Rachel Moll, Charis Pericleous, David Isenberg, Hannah Cohen, Maria Efthymiou	12
9	Monitoring of anticoagulation in thrombotic antiphospholipid syndrome 2020 ·Journal of Thrombosis and Haemostasis ·Hannah Cohen, Maria Efthymiou, Katrien Devreese	26
10	Management of anticoagulant-refractory thrombotic antiphospholipid syndrome 2020 ·The Lancet Haematology ·Hannah Cohen, (unknown), Maria Efthymiou, Pedro Gaspar, Toby Richards, David Isenberg	11
11	Antibodies against TFPI and protein C are associated with a severe thrombotic phenotype in patients with and without antiphospholipid syndrome 2018 ·Thrombosis Research ·Maria Efthymiou, Deepa J. Arachchillage, (unknown), (unknown), Thomas McDonnell, Hannah Cohen, Ian Mackie	9
12	Use of direct oral anticoagulants in antiphospholipid syndrome 2018 ·Journal of Thrombosis and Haemostasis ·Hannah Cohen, Maria Efthymiou, David Isenberg	39
13	Direct Oral Anticoagulants Use in Antiphospholipid Syndrome: Are These Drugs an Effective and Safe Alternative to Warfarin? A Systematic Review of the Literature: Comment 2017 ·Current Rheumatology Reports ·(unknown), Hannah Cohen, Beverley J. Hunt, Maria Efthymiou, Ian Mackie, Munther A. Khamashta, David Isenberg	4
14	Rivaroxaban limits complement activation compared with warfarin in antiphospholipid syndrome patients with venous thromboembolism 2016 ·Journal of Thrombosis and Haemostasis ·Deepa J. Arachchillage, Ian Mackie, Maria Efthymiou, A Chitolie, Beverley J. Hunt, David Isenberg, Munther A. Khamashta, S. J. Machin, Hannah Cohen	35
15	Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): a randomised, controlled, open-label, phase 2/3, non-inferiority trial breakdown → 2016 ·The Lancet Haematology ·Hannah Cohen, Beverley J. Hunt, Maria Efthymiou, Deepa J. Arachchillage, Ian Mackie, Simon Clawson, Yvonne Sylvestre, Samuel J. Machin, María Laura Bertolaccini, (unknown), Nicola Muirhead, Caroline J Doré, Munther A. Khamashta, David Isenberg	278
16	Protective Effects of Non-Anticoagulant Activated Protein C Variant (D36A/L38D/A39V) in a Murine Model of Ischaemic Stroke 2015 ·PLoS ONE ·Anna P. Andreou, Maria Efthymiou, Yao Yu, Helena Watts, Faruq H. Noormohamed, Daqing Ma, David A. Lane, James T. B. Crawley	13
17	Thrombin generation and factor X assays for the assessment of warfarin anticoagulation in thrombotic antiphospholipid syndrome 2015 ·Thrombosis Research ·Maria Efthymiou, Andrew Lawrie, Ian Mackie, Deepa J. Arachchillage, (unknown), Samuel J. Machin, Hannah Cohen	33
18	Interactions between rivaroxaban and antiphospholipid antibodies in thrombotic antiphospholipid syndrome 2015 ·Journal of Thrombosis and Haemostasis ·Deepa J. Arachchillage, Ian Mackie, Maria Efthymiou, David Isenberg, Samuel J. Machin, Hannah Cohen	47
19	Anti‐protein C antibodies are associated with resistance to endogenous protein C activation and a severe thrombotic phenotype in antiphospholipid syndrome 2014 ·Journal of Thrombosis and Haemostasis ·Deepa J. Arachchillage, Maria Efthymiou, Ian Mackie, Andrew Lawrie, S. J. Machin, Hannah Cohen	57
20	Rivaroxaban and warfarin achieve effective anticoagulation, as assessed by inhibition of TG and in-vivo markers of coagulation activation, in patients with venous thromboembolism 2014 ·Thrombosis Research ·Deepa J. Arachchillage, Maria Efthymiou, Ian Mackie, Andrew Lawrie, Samuel J. Machin, Hannah Cohen	25

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact